Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M301,859Revenue $M71,312Net Margin (%)21.2Z-Score5.4
Enterprise Value $M287,357EPS $4.8Operating Margin %27.2F-Score7
P/E(ttm))19.7Cash Flow Per Share $6.2Pre-tax Margin (%)23.8Higher ROA y-yY
Price/Book3.910-y EBITDA Growth Rate %3.5Quick Ratio2.1Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %-0.8Current Ratio2.5Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %7.6ROA % (ttm)11.9Higher Current Ratio y-yY
Dividend Yield %2.5Insider Buy (3m)0ROE % (ttm)21.1Less Shares Outstanding y-yY
Payout Ratio %50.0Shares Outstanding M2,829ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -13.16%3,300,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -5.5%9,045,902
JNJTweedy Browne 2014-06-30 Reduce-0.17%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -1.71%4,196,224
JNJRay Dalio 2014-06-30 Reduce-0.16%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -74.94%65,893
JNJGeorge Soros 2014-06-30 Reduce-0.05%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -51.22%50,000
JNJJoel Greenblatt 2014-06-30 Sold Out -0.01%$96.54 - $105.76
($101.02)
$ 106.275%Sold Out0
JNJJohn Hussman 2014-06-30 Reduce-0.01%$96.54 - $105.76
($101.02)
$ 106.275%Reduce -50%1,325
JNJRay Dalio 2014-03-31 Add0.12%$86.62 - $97.44
($92.6)
$ 106.2715%Add 132.34%262,993
JNJGeorge Soros 2014-03-31 Buy 0.1%$86.62 - $97.44
($92.6)
$ 106.2715%New holding, 102500 sh.102,500
JNJJoel Greenblatt 2014-03-31 Buy 0.01%$86.62 - $97.44
($92.6)
$ 106.2715%New holding, 7496 sh.7,496
JNJJohn Hussman 2014-03-31 Reduce-0.65%$86.62 - $97.44
($92.63)
$ 106.2715%Reduce -97.42%2,650
JNJPRIMECAP Management 2014-03-31 Reduce-0.15%$86.62 - $97.44
($92.6)
$ 106.2715%Reduce -10.14%12,300,986
JNJRay Dalio 2013-12-31 Add0.06%$85.61 - $95.63
($92.24)
$ 106.2715%Add 314.73%113,193
JNJPrem Watsa 2013-12-31 Reduce-15.54%$85.61 - $95.63
($92.24)
$ 106.2715%Reduce -97.12%84,700
JNJGeorge Soros 2013-12-31 Sold Out -1.2%$85.61 - $95.63
($92.24)
$ 106.2715%Sold Out0
JNJVanguard Health Care Fund 2013-12-31 Sold Out -0.85%$85.61 - $95.63
($92.24)
$ 106.2715%Sold Out0
JNJJohn Hussman 2013-12-31 Reduce-0.48%$85.61 - $95.63
($92.24)
$ 106.2715%Reduce -49.35%102,650
JNJJoel Greenblatt 2013-12-31 Sold Out -0.09%$85.61 - $95.63
($92.24)
$ 106.2715%Sold Out0
JNJJoel Greenblatt 2013-09-30 Buy 0.09%$86.17 - $94.39
($89.81)
$ 106.2718%New holding, 32599 sh.32,599
JNJRuane Cunniff 2013-09-30 Add0.03%$86.17 - $94.39
($89.81)
$ 106.2718%Add 420.69%74,495
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ James Barrow 2014-06-3017,065,2300.62.4+0.66%
JNJ Jean-Marie Eveillard 2014-06-301,623,4820.060.41+0.37%
JNJ Ruane Cunniff 2014-06-3076,01200.04+0.29%
JNJ Yacktman Fund 2014-06-304,050,0000.143.6
JNJ Tom Gayner 2014-06-30574,2000.021.7
JNJ Richard Perry 2014-06-30342,2770.010.99
JNJ Warren Buffett 2014-06-30327,1000.010.03
JNJ Prem Watsa 2014-06-3084,70000.61
JNJ Dodge & Cox 2014-06-3038,62500
JNJ Michael Price 2014-06-3035,00000.45
JNJ PRIMECAP Management 2014-06-3012,242,4200.431.4-0.48%
JNJ Tweedy Browne 2014-06-304,196,2240.159.4-1.71%
JNJ Donald Yacktman 2014-06-309,045,9020.323.8-5.5%
JNJ Mario Gabelli 2014-06-30373,1860.010.2-5.54%
JNJ Yacktman Focused Fund 2014-06-303,300,0000.123.5-13.16%
JNJ John Hussman 2014-06-301,32500.01-50%
JNJ George Soros 2014-06-3050,00000.04-51.22%
JNJ Ray Dalio 2014-06-3065,89300.05-74.94%
JNJ Joel Greenblatt 2014-06-30000Sold Out
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CULLEN JAMESDirector 2014-09-10Sell2,446$104.122.07view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.31.9view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.056.23view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.1514.1view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.3916.29view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.6813.45view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.415.02view
Caruso Dominic JVP, Finance; CFO 2013-07-18Sell30,000$90.3117.68view
CULLEN JAMESDirector 2013-05-07Sell4,929$85.424.45view
LINDQUIST SUSAN LDirector 2012-12-07Sell7,600$70.0251.79view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    "A Unique Period of Time," Revisited Sep 22 2014 
    The 4% Rule Examined Sep 11 2014 
    Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
    Rainy Day Dividend Stocks Sep 10 2014 
    3 Dividend Stocks For Retirement Sep 09 2014 
    Think Like An Owner Aug 27 2014 
    High-Yield, High-Return Investments To Increase Income While Waiting On Dividend Growth Aug 27 2014 
    Here's Why Johnson & Johnson Is a Good Investment at 52-Week Highs Aug 25 2014 
    The Most Important Financial Statement When Selecting Dividend Growth Stocks Aug 21 2014 
    A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 


    More From Other Websites
    Scientists grapple with ethics in rush to release Ebola vaccines Sep 29 2014
    Inovio/GeneOne Life Science Collaborate for Ebola Vaccine Sep 25 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 24 2014
    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results Sep 23 2014
    Why investors prefer dividends in a low interest rate environment Sep 23 2014
    Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Lower Sep 23 2014
    Kinvey Announces Series B--The MBaaS Battle Continues Sep 23 2014
    [video] The Personal Story Behind WSJ’s ‘Deadly Medicine’ Sep 22 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 19 2014
    Gilead's Zydelig Approved In EU; Imbruvica In Wings Sep 19 2014
    Today's Market Thorns, Roses and All Time Highs... Sep 18 2014
    Corporate bond ratings do not discern risk Sep 18 2014
    AstraZeneca and Eli Lilly to unite for Alzheimer's drug challenge Sep 16 2014
    The Keys In This Market: Income & Growth Sep 16 2014
    Lawyer grills DePuy executive over safety studies for Pinnacle hips Sep 15 2014
    3 Companies Investing In Stem Cell Research Sep 14 2014
    Adapting Listerine to a Global Market Sep 12 2014
    Addressing Disengagement And Depression Lifts Workers Sep 12 2014
    Insider Trading Alert - JNJ, EL And GPI Traded By Insiders Sep 12 2014
    Medivation Eyes Blockbuster As Cancer Drug Gets An OK Sep 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 11 months ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK